Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Neurooncology: current findings and challenges for the future

Neurooncology: current findings and challenges for the future editorial memo (2013) 6:225–226 DOI 10.1007/s12254-013-0091-y Neurooncology: current findings and challenges for the future Silvia Hofer Received: 28 May 2013 / Accepted: 29 May 2013 / Published online: 22 June 2013 © Springer-Verlag Wien 2013 Primary central nervous system (CNS) tumors com- Two biomarkers that are newly integrated into clinical prise approximately of 120 histological subtypes. Thus, practice deserve a more detailed description. it seems reasonable to concentrate primarily on some For anaplastic WHO grade III oligodendrogliomas, common entities. Most primary CNS tumors of adults are the loss of 1p/19q (LOH 1p/19q) due to an unbalanced of glial origin and if they belong to WHO grade II–IV, they translocation improves both survival and the response diffusely infiltrate the normal brain ab initio, i.e., pre- to therapy, and is thus, both a prognostic and a predic- therapeutically. With current standard treatment they tive marker. The most recent long-term follow-up from cannot be cured. And, here lies an immense challenge two large randomized Phase III trials [2, 3] call for a rou- for the neurooncology community. tine testing of this marker with PCR or FISH technique in Gliomas are defined by histomorphological criteria, WHO grade III gliomas. A marked overall survival http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Neurooncology: current findings and challenges for the future

Loading next page...
 
/lp/springer-journals/neurooncology-current-findings-and-challenges-for-the-future-8MOEBNm00x

References (8)

Publisher
Springer Journals
Copyright
Copyright © 2013 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-013-0091-y
Publisher site
See Article on Publisher Site

Abstract

editorial memo (2013) 6:225–226 DOI 10.1007/s12254-013-0091-y Neurooncology: current findings and challenges for the future Silvia Hofer Received: 28 May 2013 / Accepted: 29 May 2013 / Published online: 22 June 2013 © Springer-Verlag Wien 2013 Primary central nervous system (CNS) tumors com- Two biomarkers that are newly integrated into clinical prise approximately of 120 histological subtypes. Thus, practice deserve a more detailed description. it seems reasonable to concentrate primarily on some For anaplastic WHO grade III oligodendrogliomas, common entities. Most primary CNS tumors of adults are the loss of 1p/19q (LOH 1p/19q) due to an unbalanced of glial origin and if they belong to WHO grade II–IV, they translocation improves both survival and the response diffusely infiltrate the normal brain ab initio, i.e., pre- to therapy, and is thus, both a prognostic and a predic- therapeutically. With current standard treatment they tive marker. The most recent long-term follow-up from cannot be cured. And, here lies an immense challenge two large randomized Phase III trials [2, 3] call for a rou- for the neurooncology community. tine testing of this marker with PCR or FISH technique in Gliomas are defined by histomorphological criteria, WHO grade III gliomas. A marked overall survival

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Jun 22, 2013

There are no references for this article.